Targets

Target Filters...

This is where graphics are reside..

Name	Gene	Development Level	Target Family	Log Novelty	Pubmed Score	Antibody Count
Proto-oncogene Wnt-1	WNT1	Tbio	Non-IDG	-2.73870	492.7	294
Mediator of RNA polymerase II transcription subunit 7	MED7	Tbio	Enzyme	-1.04585	10.2	155
Mediator of RNA polymerase II transcription subunit 25	MED25	Tbio	Enzyme	-1.76765	56.0	62
Trimethylguanosine synthase	TGS1	Tbio	Enzyme	-1.36236	24.4	85
Mediator of RNA polymerase II transcription subunit 23	MED23	Tbio	Enzyme	-1.42178	30.0	128
Angiopoietin-related protein 4	ANGPTL4	Tbio	Non-IDG	-2.41477	298.0	270
Krueppel-like factor 5	KLF5	Tchem	Transcription Factor	-2.19039	189.7	186
Cyclin-dependent kinase 19	CDK19	Tchem	Kinase	-1.30571	16.4	133
Mediator of RNA polymerase II transcription subunit 1	MED1	Tbio	Enzyme	-1.88337	79.6	319
Retinoic acid receptor RXR-alpha	RXRA	Tclin	Nuclear Receptor	-2.47322	228.6	266

	Tbio	48 \| 10,625
	Tchem	23 \| 1,890
	Tdark	7 \| 7,003
	Tclin	6 \| 602

	preweaning lethality, complete...	9 \| 633
	embryonic lethality prior to t...	3 \| 187
	preweaning lethality, incomple...	3 \| 260
	abnormal embryo size	2 \| 112
	decreased circulating amylase ...	2 \| 24
	decreased lean body mass	2 \| 195
	decreased leukocyte cell numbe...	2 \| 54
	increased circulating alkaline...	2 \| 119
	abnormal behavior	1 \| 226
	abnormal bone structure	1 \| 131
	abnormal coping response	1 \| 12
	abnormal cornea morphology	1 \| 24
	abnormal eye morphology	1 \| 38
	abnormal gait	1 \| 51
	abnormal motor capabilities-co...	1 \| 4
	abnormal placenta size	1 \| 10
	abnormal respiratory quotient	1 \| 9
	abnormal skin condition	1 \| 6
	abnormal tail bud morphology	1 \| 6
	abnormal tooth morphology	1 \| 24
	absent heartbeat	1 \| 6
	absent optic nerve	1 \| 1
	decreased CD4-positive, CD25-p...	1 \| 24
	decreased KLRG1+ CD4 alpha bet...	1 \| 2
	decreased Ly6C low monocyte nu...	1 \| 23
	decreased anxiety-related resp...	1 \| 12
	decreased body length	1 \| 108
	decreased circulating alkaline...	1 \| 41
	decreased circulating calcium ...	1 \| 33
	decreased circulating choleste...	1 \| 85
	decreased circulating glucose ...	1 \| 121
	decreased circulating serum al...	1 \| 79
	decreased circulating sodium l...	1 \| 18
	decreased fasted circulating g...	1 \| 49
	decreased mean corpuscular hem...	1 \| 19
	decreased startle reflex	1 \| 48
	decreased thermal nociceptive ...	1 \| 4
	decreased threshold for audito...	1 \| 32
	decreased total body fat amoun...	1 \| 186
	embryonic lethality prior to o...	1 \| 148
	female infertility	1 \| 34
	hydrops fetalis	1 \| 22
	impaired glucose tolerance	1 \| 52
	increased Ly6C high monocyte n...	1 \| 12
	increased body weight	1 \| 42
	increased circulating free fat...	1 \| 17
	increased circulating glycerol...	1 \| 11
	increased circulating triglyce...	1 \| 24
	increased fasted circulating g...	1 \| 68
	increased leukocyte cell numbe...	1 \| 37
	increased mean corpuscular hem...	1 \| 93
	increased or absent threshold ...	1 \| 128
	increased thermal nociceptive ...	1 \| 9
	long tibia	1 \| 13
	male infertility	1 \| 62
	microphthalmia	1 \| 15
	pale liver	1 \| 5
	pale yolk sac	1 \| 12
	persistence of hyaloid vascula...	1 \| 22
	short tibia	1 \| 82

	ovarian cancer	53 \| 8,491
	osteosarcoma	52 \| 7,933
	psoriasis	41 \| 6,685
	Cancer	34 \| 2,346
	medulloblastoma, large-cell	33 \| 6,234
	glioblastoma	31 \| 5,572
	lung cancer	25 \| 4,473
	malignant mesothelioma	23 \| 3,163
	Obesity	22 \| 616
	atypical teratoid / rhabdoid tumor	22 \| 4,369
	intraductal papillary-mucinous neoplasm (IPMN)	22 \| 3,289
	astrocytoma	21 \| 1,493
	diabetes mellitus	21 \| 1,663
	invasive ductal carcinoma	20 \| 2,950
	intraductal papillary-mucinous adenoma (IPMA)	19 \| 2,956
	ulcerative colitis	18 \| 2,087
	Breast cancer	17 \| 3,098
	intraductal papillary-mucinous carcinoma (IPMC)	17 \| 2,988
	primitive neuroectodermal tumor	17 \| 3,031
	breast carcinoma	16 \| 1,614
	pituitary cancer	16 \| 1,972
	acute quadriplegic myopathy	15 \| 1,157
	lung adenocarcinoma	15 \| 2,714
	Carcinoma	14 \| 2,147
	Pick disease	14 \| 1,893
	Rheumatoid Arthritis	14 \| 1,170
	ductal carcinoma in situ	14 \| 1,745
	group 4 medulloblastoma	14 \| 1,875
	oligodendroglioma	14 \| 2,849
	tuberculosis	14 \| 1,563
	Metabolic syndrome X	13 \| 155
	ependymoma	13 \| 2,514
	Mammary Neoplasms	12 \| 410
	fibroadenoma	12 \| 557
	lung carcinoma	12 \| 2,844
	Atherosclerosis	11 \| 275
	Endometriosis	11 \| 535
	Hyperglycemia	11 \| 120
	Lipid metabolism disorder	11 \| 102
	group 3 medulloblastoma	11 \| 2,254
	Diabetes Mellitus, Non-Insulin-Dependent	10 \| 161
	Fatty liver disease	10 \| 86
	Multiple myeloma	10 \| 1,327
	Prostatic Neoplasms	10 \| 471
	adrenocortical carcinoma	10 \| 1,427
	astrocytic glioma	10 \| 2,241
	autosomal dominant Emery-Dreifuss muscular dystrophy	10 \| 499
	non-small cell lung cancer	10 \| 2,798
	pediatric high grade glioma	10 \| 2,712
	pilocytic astrocytoma	10 \| 3,086
	Atopic dermatitis	9 \| 944
	Coronary artery disease	9 \| 240
	Diabetes Mellitus, Experimental	9 \| 106
	Hypertensive disease	9 \| 193
	Insulin Resistance	9 \| 50
	Liver carcinoma	9 \| 217
	interstitial cystitis	9 \| 2,299
	juvenile dermatomyositis	9 \| 1,189
	pancreatic cancer	9 \| 2,300
	posterior fossa group B ependymoma	9 \| 1,530
	Hyperinsulinism	8 \| 63
	Hypertension	8 \| 293
	Kidney Failure, Chronic	8 \| 45
	acute myeloid leukemia	8 \| 785
	colon cancer	8 \| 1,475
	dermatomyositis	8 \| 966
	subependymal giant cell astrocytoma	8 \| 2,287
	tuberculosis and treatment for 6 months	8 \| 686
	Cerebrovascular disease	7 \| 231
	Heart disease	7 \| 279
	Intellectual disability	7 \| 573
	Lipodystrophy	7 \| 32
	Liver disease	7 \| 219
	Osteoporosis	7 \| 259
	adult high grade glioma	7 \| 2,148
	medulloblastoma	7 \| 1,524
	pancreatic ductal adenocarcinoma liver metastasis	7 \| 1,795
	primary pancreatic ductal adenocarcinoma	7 \| 1,271
	spina bifida	7 \| 1,064
	Colonic Neoplasms	6 \| 126
	Inflammation	6 \| 109
	Myocardial Ischemia	6 \| 169
	chronic lymphosyte leukemia	6 \| 232
	cystic fibrosis	6 \| 1,670
	mucosa-associated lymphoid tissue lymphoma	6 \| 480
	nasopharyngeal carcinoma	6 \| 1,056
	Alzheimer's disease	5 \| 644
	Asthma	5 \| 349
	Crohn Disease	5 \| 97
	Crohn's disease	5 \| 304
	Drug-Induced Liver Injury	5 \| 118
	Duchenne muscular dystrophy	5 \| 602
	Kidney disease	5 \| 397
	Mammary Neoplasms, Experimental	5 \| 149
	Neoplasm Metastasis	5 \| 138
	Polycystic Ovary Syndrome	5 \| 334
	Reperfusion Injury	5 \| 84
	Schizophrenia	5 \| 503
	aldosterone-producing adenoma	5 \| 664
	non primary Sjogren syndrome sicca	5 \| 840

	Blood and immune system	84 \| 17,994
	Cardiovascular System	84 \| 17,957
	Digestive Tract	84 \| 18,472
	Endocrine System	84 \| 18,511
	Female tissues	84 \| 18,646
	Liver and Pancreas	84 \| 18,135
	Male tissues	84 \| 17,968
	Nervous System	84 \| 18,560
	Respiratory system	84 \| 17,483
	Skin and soft tissues	84 \| 18,114
	Urinary Tract	84 \| 18,443

	Enzyme	32 \| 4,146
	Non-IDG	22 \| 11,969
	Transcription Factor	14 \| 1,400
	Epigenetic	7 \| 242
	Kinase	4 \| 634
	Nuclear Receptor	4 \| 48
	Transporter	1 \| 473

Development Level

Collection

IMPC Phenotype

Disease

Tissue

Target Family

Reactome Pathway

Drug Target Ontology

Target Development Level

Target Family

PANTHER Protein Ontology

Ligand

GTEx Tissue

HPA RNA Tissue

HPA Protein Tissue

HPM Tissue

JAX/MGI Phenotype

OMIM Phenotype

GWAS Trait

GO Component

UniProt Keywords

Grant Funding IC

Grant Activity

Data Source

	Transcriptional regulation of ...	84 \| 84
	Signal Transduction	2,515 \| 2,515
	Immune System	2,183 \| 2,183
	Metabolism	2,131 \| 2,131
	Gene Expression	1,754 \| 1,754
	Metabolism of proteins	1,544 \| 1,544
	Innate Immune System	1,375 \| 1,375
	Signaling by GPCR	1,329 \| 1,329
	Developmental Biology	1,028 \| 1,028
	GPCR downstream signaling	1,015 \| 1,015
	Post-translational protein mod...	1,004 \| 1,004
	Adaptive Immune System	938 \| 938
	Disease	855 \| 855
	Generic Transcription Pathway	852 \| 852
	Cytokine Signaling in Immune s...	803 \| 803
	Metabolism of lipids and lipop...	797 \| 797
	Vesicle-mediated transport	705 \| 705
	Hemostasis	669 \| 669
	Transmembrane transport of sma...	668 \| 668
	Membrane Trafficking	608 \| 608
	Cell Cycle	572 \| 572
	Neutrophil degranulation	542 \| 542
	Axon guidance	541 \| 541
	Signaling by Interleukins	500 \| 500
	Cell Cycle, Mitotic	470 \| 470
	Signalling by NGF	467 \| 467
	GPCR ligand binding	456 \| 456
	Gastrin-CREB signalling pathwa...	435 \| 435
	Class I MHC mediated antigen p...	430 \| 430
	Olfactory Signaling Pathway	430 \| 430
	Fc epsilon receptor (FCERI) si...	423 \| 423
	Cellular responses to stress	415 \| 415
	DAP12 interactions	409 \| 409
	Infectious disease	391 \| 391
	NGF signalling via TRKA from t...	378 \| 378
	Signaling by Rho GTPases	378 \| 378
	Signaling by PDGF	367 \| 367
	Diseases of signal transductio...	359 \| 359
	Transcriptional Regulation by ...	356 \| 356
	Signaling by EGFR	355 \| 355
	Metabolism of amino acids and ...	353 \| 353
	DAP12 signaling	346 \| 346
	Downstream signal transduction	343 \| 343
	Neuronal System	343 \| 343
	Organelle biogenesis and maint...	334 \| 334
	Signaling by VEGF	329 \| 329
	Signaling by SCF-KIT	327 \| 327
	Class A/1 (Rhodopsin-like rece...	322 \| 322
	VEGFA-VEGFR2 Pathway	321 \| 321
	FCERI mediated MAPK activation	316 \| 316
	Signaling by Insulin receptor	312 \| 312
	Antigen processing: Ubiquitina...	301 \| 301
	Extracellular matrix organizat...	292 \| 292
	Signaling by Type 1 Insulin-li...	290 \| 290
	Signaling by Wnt	290 \| 290
	IGF1R signaling cascade	289 \| 289
	IRS-related events triggered b...	289 \| 289
	Insulin receptor signalling ca...	288 \| 288
	Metabolism of carbohydrates	288 \| 288
	DNA Repair	286 \| 286
	IRS-mediated signalling	285 \| 285
	MAPK family signaling cascades	283 \| 283
	Asparagine N-linked glycosylat...	282 \| 282
	Signaling by the B Cell Recept...	282 \| 282
	SLC-mediated transmembrane tra...	280 \| 280
	Deubiquitination	277 \| 277
	Interferon Signaling	275 \| 275
	Platelet activation, signaling...	274 \| 274
	NCAM signaling for neurite out...	268 \| 268
	M Phase	266 \| 266
	Interleukin-3, 5 and GM-CSF si...	262 \| 262
	RET signaling	261 \| 261
	Signalling to ERKs	254 \| 254
	Interleukin-2 signaling	253 \| 253
	Immunoregulatory interactions ...	252 \| 252
	RHO GTPase Effectors	249 \| 249
	VEGFR2 mediated cell prolifera...	249 \| 249
	Signalling to RAS	247 \| 247
	Interleukin receptor SHC signa...	246 \| 246
	G alpha (i) signalling events	245 \| 245
	Fatty acid, triacylglycerol, a...	244 \| 244
	Signaling by Leptin	244 \| 244
	Prolonged ERK activation event...	243 \| 243
	MAPK1/MAPK3 signaling	242 \| 242
	Frs2-mediated activation	241 \| 241
	HIV Infection	241 \| 241
	ARMS-mediated activation	240 \| 240
	Signalling to p38 via RIT and ...	240 \| 240
	Chromatin modifying enzymes	237 \| 237
	Chromatin organization	237 \| 237
	GRB2 events in EGFR signaling	236 \| 236
	RAF/MAP kinase cascade	236 \| 236
	SHC1 events in EGFR signaling	236 \| 236
	SOS-mediated signalling	236 \| 236
	Processing of Capped Intron-Co...	235 \| 235
	Biological oxidations	215 \| 215
	Keratinization	213 \| 213
	Transmission across Chemical S...	210 \| 210
	rRNA processing	209 \| 209
	Ion channel transport	204 \| 204
	Phospholipid metabolism	202 \| 202